Symeres and Ambagon team up to target ‘undruggable’ proteins in colorectal cancer
Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
Former Interim CEO takes charge to drive strategic growth, strengthen clinical excellence, and advance patient-centric oncology innovation
New facility in Sector 51 offers advanced, affordable, and patient-centric dialysis services for NCR patients
As part of the deal, Red Nucleus also gains indirect ownership of the company’s Indian arm
Safety was equally impressive. ENV-294 was well tolerated
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
Institute signs four MoUs, launches two products and marks 75 years with renewed focus on lab-to-market commercialisation
The patient, suffering from calcific severe aortic stenosis—a dangerous narrowing of the heart valve caused by calcium buildup—had run out of standard treatment options
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
Subscribe To Our Newsletter & Stay Updated